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Context: Kallmann syndrome (KS) and CHARGE syndrome are rare heritable disorders in which
anosmia and hypogonadotropic hypogonadism co-occur. KS is genetically heterogeneous, and
there are at least eight genes involved in its pathogenesis, whereas CHARGE syndrome is caused
by autosomal dominant mutations in only one gene, the CHD7 gene. Two independent studies
showed that CHD7 mutations can also be found in a minority of KS patients.
Objective:Weaimedto investigatewhetherCHD7mutations cangive rise to isolatedKSorwhether
additional features of CHARGE syndrome always occur.
Design:We performed CHD7 analysis in a cohort of 36 clinically well-characterized Dutch patients
with KS but without mutations in KAL1 and with known status for the KS genes with incomplete
penetrance, FGFR1, PROK2, PROKR2, and FGF8.
Results: We identified three heterozygous CHD7 mutations. The CHD7-positive patients were
carefully reexamined and were all found to have additional features of CHARGE syndrome.
Conclusion: The yield of CHD7 analysis in patients with isolated KS seems very low but increases
when additional CHARGE features are present. Therefore, we recommend performing CHD7 anal-
ysis in KS patients who have at least two additional CHARGE features or semicircular canal anom-
alies. Identifying a CHD7 mutation has important clinical implications for the surveillance and
genetic counseling of patients. (J Clin Endocrinol Metab 97: E858–E862, 2012)
Kallmann syndrome (KS) is characterized by the com-bination of anosmia and hypogonadotropic hypo-
gonadism (HH) (1). Anosmia, or the inability to smell, is
the result of olfactory bulb defects (2), whereas HH pres-
ents as absent or impaired pubertal maturation and is
caused by GnRH deficiency (3). KS is clinically and ge-
netically very heterogeneous (Supplemental Table 1, pub-
lishedonTheEndocrineSociety’s JournalsOnlineweb site
at http://jcem.endojournals.org) (3–10). At present, mu-
tations in eight genes explain approximately 25–35% of
KS cases. Heterozygous loss-of-function mutations in the
CHD7 gene were identified in patients with normosmic idio-
pathic HH (nIHH), KS, and CHARGE syndrome (11, 12).
CHARGE syndrome is a highly variable disorder in
which congenital anomalies, multisensory impairment,
and variable mental retardation can occur (OMIM
214800). CHARGE is an acronym for ocular coloboma,
heart defects, choanal atresia, retardation of growth
and/ordevelopment, genital hypoplasia andear anomalies
combinedwithdeafness (13).HHandanosmiaarepresent
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in the majority of patients with CHARGE syndrome (14).
Recently, we showed that HH and anosmia co-occur in
CHARGE syndrome (4), which means that KS is part of
the phenotypic spectrum of CHARGE syndrome. CHD7
mutations are found in more than 90% of patients with
typical CHARGE syndrome (5).
Conversely, CHD7 mutations are not a major cause of
KS, because only 3–5% of patients with nIHH/KS were
found to have aCHD7mutation in two independent studies
(11, 12). The first study identified sevenCHD7mutations in
a cohort of 197 patients with nIHH/KS (seven of 197 
3.6%) (12). Four of theCHD7-positive patients had nIHH,
whereas three patients had KS. In the CHD7-positive pa-
tients, no other features of CHARGE syndrome were pres-
ent, except for cleft lip/palate and hearing loss, which can
occur inbothCHARGEsyndromeandKS.Theauthors con-
cluded thatCHD7mutations can give rise to isolated nIHH
and KS. The second study, performed by our group, found
three CHD7 mutations in a cohort of 56 Japanese/North
American nIHH/KS patients in whom mutations in KAL1,
FGFR1,PROK2, andPROKR2hadbeenexcluded (threeof
565.4%) (11). The threeCHD7-positive patientswere all
diagnosed with KS but on extensive clinical reevaluation
were found to have several other features of CHARGE
syndrome.
Because of the conflicting data from these two studies,
we decided to investigate whether CHD7 mutations can
give rise to isolatedKS inan independent cohort.We there-
fore analyzed the CHD7 gene in 36 clinically well-char-
acterized Dutch KS patients.
Patients and Methods
Patients
A cohort of 36 Dutch KS patients (seven women, 29 men),
without a hemizygous mutation in KAL1 in the male patients,
was informed about this study via their pediatric endocrinolo-
gist, endocrinologist, gynecologist, or clinical geneticist. The pa-
tients gave their informed consent for sequence analysis of
FGFR1, PROK2, PROKR2, FGF8, and CHD7 and for collec-
tion of their medical data via a questionnaire and/or retrospec-
tive chart review. The KS diagnosis was based on the presence of
HH, defined as no pubertal maturation in combination with
normal or low serum gonadotropins and low sex steroids, in
combination with a smell deficit identified from the patient’s
history and/or formal smell testing. TheCHD7-positive patients
who were identified in this study, were carefully reevaluated for
features of CHARGE syndrome and underwent formal smell
testing [University of Pennsylvania Smell Identification Test
(UPSIT); Sensonics Inc., Haddon Heights, NJ; www.sensonics.
com) (15)]. This studywas approved by the ethical review board
of the University Medical Center Groningen (UMCG).
DNA analysis
DNA was extracted from peripheral blood lymphocytes
using standard procedures. All individual exons of the CHD7
gene were amplified by PCR, and direct sequencing was per-
formed on an ABI 3730 automated DNA sequencer (Applied
Biosystems, Foster City, CA) as described previously (14). The
GenBank accession number NM_017780.2 was used as ref-
erence sequence for the CHD7 gene. The A of ATG was des-
ignated number 1. The intron sequences of theCHD7 gene can
be found in NG_007009.1.
Results
The clinical features of the 36 Dutch KS patients and the
results of DNA analysis are summarized in Table 1 and
Supplemental Table 2. Heterozygous CHD7 mutations
were identified in three patients, who were carefully re-
examined for additional features of CHARGE syndrome.
Patient 1was diagnosedwith KS at age 16 and received
hormone replacement therapy (HRT). She had a bilateral
cleft lip/palate and mixed hearing loss. At age 20, she was
TABLE 1. Dutch patients with KS who were found to have a mutation in the CHD7 gene: KAL1, FGFR1, PROK2,
PROKR2, and FGF8 status, results of CHD7 analysis, and an overview of the clinical characteristics and family history
Patient
no.









1 F — c.4015CT; p.Arg1339X Cleft lip and palate, bilateral mixed
hearing loss, retinal coloboma,
balance disturbance, mild scoliosis,
olfactory bulb aplasia
—
2 M — c.5316GA; p.Trp1772X Bilateral hearing loss, cleft palate,
short stature, bicuspid aortic valve,
abnormal external ears, synkinesia
—
3 M — c.6322GA; p.Gly2108Arg
de novo
Bilateral sensorineural hearing loss,
hypoplasia of cochlea and
semicircular canals
—
F, Female; M, male.
a —, Normal results of KAL1, FGFR1, PROK2, PROKR2, and FGF8 analysis.
b —, Negative family history.
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reevaluated at the UMCG’s multidisciplinary CHARGE
outpatient clinic andwas found to have aCHD7 nonsense
mutation (c.4015CT; p.Arg1339X). Her history re-
vealed delayed motor development and feeding difficul-
ties. She also had balance disturbance [but a computed
tomography (CT) scan of the temporal bone had not been
performed], mild scoliosis, and impaired vision. Ophthal-
mological reexamination revealedbilateral retinal colobo-
mas.Her external earswere normal, and ultrasoundof the
heart and kidneys showedno abnormalities. Anosmiawas
confirmed by formal smell testing (UPSIT score 12 of 40),
and reevaluationof an earliermagnetic resonance imaging
brain scan showed olfactory bulb aplasia. In retrospect,
she has typical CHARGE syndrome.
Patient 2 was diagnosed with KS at age 16 and was
started on HRT. He had severe bilateral hearing loss. He
was reexamined at age 31 at the Department of Human
Genetics, Radboud University Nijmegen Medical Center,
and was shown to harbor a CHD7 nonsense mutation
(c.5316GA; p.Trp1772X). His history revealed mildly
delayed motor development and a cleft palate. He had
short stature, synkinesia, and small earlobes. An ultra-
soundofheart andkidneys revealedabicuspidaortic valve
and normal kidneys. He has not undergone imaging of the
inner ear. Formal smell testing showed that he had anos-
mia (UPSIT score 7 of 40). After reevaluation, he was
found to have typical CHARGE syndrome.
Patient 3 was diagnosed with KS at age 14 and started
with HRT. He had severe bilateral sensorineural hearing
loss.Hewas reevaluatedatage17at theUMCG’sCHARGE
outpatient clinic. CHD7 analysis revealed a de novo CHD7
missensemutation (c.6322GA;p.Gly2108Arg).The glycine
at position 2108 is highly conserved, and the amino acid
substitution is considered pathogenic by three prediction
programs (SIFT, PolyPhen, andAlignGVGD) (16–18). In
addition, this variant was previously identified in three
other index patients with CHARGE syndrome and is
therefore highly likely to be pathogenic (www.CHD7.org;
Janssen, N., J. E. H. Bergman, M. A. Swertz, L. Traneb-
jaerg, M. Lodahl, J. Schoots, R. M. W. Hofstra, C. M. A.
van Ravenswaaij-Arts, and L. H. Hoefsloot, submitted
manuscript). Patient 3 had delayed motor development
and balance disturbance.He has a normal intelligence and
normal external ears, eyes, kidneys, and heart. Anosmia
was confirmedwith the UPSIT (score 9 of 40). A temporal
bone CT scan showed hypoplasia of the cochlea and semi-
circular canals, a very specific and frequent feature in
CHARGE syndrome, but otherwise, the patient did not
fulfill the clinical criteria for CHARGE syndrome (5).
None of the patients with a CHD7mutation had an addi-
tional mutation in FGFR1, PROK2, PROKR2, or FGF8,
whereas six other patients of our cohort harbored a heterozy-
gous missense variant in the PROKR2 gene [c.254GA;
p.Arg85His (4x), c.254GT; p.Arg85Leu, and c.791GA;
p.Arg264His], and one patient had a heterozygous variant in
FGF8 (c.86_103dup; p.Gly29_Arg34dup) (see Supplemen-
tal Table 2 and Information).
Discussion
Our research question was whether CHD7 mutations
could be identified in KS patients without additional
CHARGEfeatures.We restrictedour study toKSpatients,
because we have previously shown that HH is associated
with anosmia in patients with a CHD7mutation (4), and
therefore we assumed that the chance to find a CHD7
mutation in normosmic IHH patients without CHARGE
features would be even lower.
We identified three CHD7 mutations in 36 Dutch KS
patients (three of 36  8.3%). All three patients had ad-
ditional features of CHARGE syndrome on careful reex-
amination, which is in agreement with our previous study
(11).Hearing losswas themost frequent feature seen in the
CHD7-positive KS patients in our study (Table 1) and in
other published studies (11, 12); it was found in seven of
13CHD7-positiveKSpatients.However, hearing loss can
also occur in patients with a mutation in the KAL1,
FGFR1, or FGF8 gene (Supplemental Table 1) (7, 9).
Other features that were repeatedly found in CHD7-pos-
itive KS patients were a cleft lip/palate (five of 13), short
stature (three of 13), and balance disturbance (three of 13)
(Table 1) (11, 12).
Wedid not identify aCHD7mutation in 30KSpatients
without additional CHARGE features (Supplemental Ta-
ble 2), which suggests that CHD7 mutations are not a
frequent cause of isolated KS. Recently, CHD7 analysis
was also performed in a cohort of 30 Finnish KS patients
(19). Although three KS patients displayed additional
CHARGE features, no CHD7 mutations were identified
in this cohort. Additional studies in large cohorts of clin-
ically well-characterized KS patients are needed to esti-
mate the frequency of CHD7 mutations in KS patients
more reliably. In addition, it would be useful to know
whether the CHD7-positive patients in the study by Kim
et al. (12) underwent formal smell testing and were care-
fully reevaluated after theCHD7mutationwas identified,
because otherwise subtle features of CHARGE syndrome
couldhavebeenmissed.Another limitationof the studyby
Kim et al. (12) is that it is unclear whetherCHD7 analysis
was performed in the parents of the patients with aCHD7
missense variant to give further proof that the five iden-
tified missense variants are indeed pathogenic.
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Based on the results of this study and the literature, our
advice is to evaluate KS patients carefully for features of
CHARGE syndrome by taking a detailed case history and
physical examination. If the case history reveals thatwalk-
ing without support was delayed, that the patient was
unable to crawl without resting the head on the floor (5-
point crawling), and that the patient was unable to ride a
bicycle without side-stabilizers, the patient probably suf-
fered from balance disturbance (20). Imaging of the semi-
circular canals (preferably a temporal bone CT scan) is
indicated in all KS patients who are suspected of balance
disturbance. Our advice is to perform CHD7 analysis in
KSpatientswhohave at least twoof the following features
of CHARGE syndrome: ocular coloboma, choanal atre-
sia/stenosis, characteristic external ear anomaly, cranial
nerve dysfunction (facial palsy, sensorineural hearing loss,
or hypoplastic cranial nerves on imaging), or balance dis-
turbance. In addition, CHD7 analysis is recommended in
all KS patients with semicircular canal anomalies, irre-
spective of other CHARGE features. These recommenda-
tions are in linewithour2011 recommendation forCHD7
analysis in patients suspected of CHARGE syndrome (5).
Identifying a CHD7 mutation has important clinical
implications. First, the CHD7-positive patient should be
screened for additional CHARGE features, because subtle
features can remain undetected but can have therapeutic
consequences, e.g. unilateral renal agenesis. For recom-
mendations on screening, we refer to the clinical surveil-
lance schedule in Bergman et al. (5). Second, genetic coun-
seling is indicated, because the patient has a 50% chance
of transmitting theCHD7mutation tohis orheroffspring.
The offspringmay develop amore severemanifestation of
CHARGE syndrome, because the syndrome is highly vari-
able, even within families (5). The possibility of prenatal
diagnosis and preimplantation genetic diagnosis should
therefore be discussed.
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